S. 1818In Committee
Prescription Drug Price Relief Act of 2025
Require HHS to identify excessively priced brand-name drugs and remove exclusivity to speed lower-cost generic and biosimilar competition
Plain-English overview
What this bill does
Require HHS to identify excessively priced brand-name drugs and remove exclusivity to speed lower-cost generic and biosimilar competition
Key points
- Require annual drug price reviews
- Require manufacturer financial reporting
- Authorize open nonexclusive licenses
- Revoke brand name exclusivity
Current status
Where it stands
Status
In Committee
Latest action
2025-05-20 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related context
Topics and policy areas
undefinedHealth